Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLK2 | Q86UE8 | 7/20 | 0.47 |
| ▸ | GSK3B | P49841 | 3/20 | 0.45 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | AKT2 | P31751 | 5/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL393970 | 0.95 | NTRK1 (0.44) | TLK2GSK3BMAPK14RETNTRK1 | |
| SCHEMBL398243 | 0.93 | TLK2 (0.48) | TLK2GSK3BJAK3AKT2RET | |
| SCHEMBL396159 | 0.89 | FLT3 (0.47) | TLK2RETNTRK1AURKA | |
| SCHEMBL397245 | 0.89 | MAPK14 (0.37) | TLK2GSK3BJAK3MAPK14NTRK1 | |
| SCHEMBL399058 | 0.88 | FLT3 (0.48) | TLK2GSK3BJAK3NTRK1AURKA | |
| SCHEMBL396850 | 0.87 | NTRK1 (0.53) | TLK2NTRK1AURKA | |
| SCHEMBL397868 | 0.87 | NTRK1 (0.52) | RETNTRK1AURKA | |
| SCHEMBL396166 | 0.85 | TLK2 (0.47) | TLK2GSK3BJAK3AKT2MAPK14 | |
| SCHEMBL396429 | 0.85 | NTRK1 (0.40) | TLK2GSK3BJAK3NTRK1AURKA | |
| SCHEMBL394525 | 0.85 | FLT3 (0.51) | TLK2NTRK1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101608-B2 | 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems | IRM LLC, a Delware Limited Corporation (BM) | 2012-01-24 | — | — | US | claimed |
| US-8101608-B2 | 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems | IRM LLC, a Delware Limited Corporation (BM) | 2012-01-24 | — | — | US | disclosed |